13 results about "ISG15" patented technology

This invention relates to the field of tumor molecular biology, specifically providing the application of targeting the ISG15 protein in chemotherapy sensitization drugs and prognostic assessment for B-cell lymphoma. This invention also provides the use of the ISG15 protein as a biomarker in the preparation of prognostic assessment products for B-cell lymphoma. This invention effectively reverses chemotherapy-induced senescence-related drug resistance and restores the chemosensitivity of tumor cells by inhibiting the ISG15 pathway; simultaneously, the ISG15 expression level can serve as a biomarker for prognostic assessment of B-cell lymphoma. This invention provides a new technical solution for overcoming chemotherapy resistance in B-cell lymphoma and assessing patient prognosis.

This application relates to the field of biomedical detection technology, specifically to a combination of biomarkers for assessing the severity of viremia in Chikungunya virus patients and its application. The combination of biomarkers for assessing the severity of viremia in Chikungunya virus patients includes one or more of the following biomarkers: TAP1, ISG15, CMPK2, GBP4, OTOF, and SIGLEC1. The biomarker combination provided in this application can objectively and quantitatively reflect the activity of viral replication and the strength of the immune response in the patient, thereby achieving accurate assessment of the severity of viremia. This solves the problem in existing technologies that mainly rely on qualitative or semi-quantitative detection of viral nucleic acids and lack assessment methods closely related to the host's pathological state.

The invention discloses a CDKN2A and ISG15 interaction key site THR95 and an application of the CDKN2A and ISG15 interaction key site THR95. The invention particularly relates to application of the key site in preparation of a product for diagnosing or inhibiting tumor immune escape. The invention provides a new target spot and a new method for diagnosis and treatment of tumor immune escape by researching key sites of interaction of CDKN2A and ISG15, and has important clinical application value.

The present application relates to the technical field of biological medicine, and in particular to application of hemoglobin oxygen carrier (HBOCs) in preparation of antiviral drugs, and provides a novel mechanism of action of HBOCs, and reveals that HBOCs change the distribution of immune cell subgroups in mouse bone marrow, up-regulate the expression level of antiviral genes, thereby enhancing the resistance of the body to viruses, and provides a new idea for development and preparation of antiviral drugs. Isg15 ​

This invention pertains to polypeptide agents that specifically bind to human Interferon-stimulated gene 15 (ISG15). In particular, it describes immunoglobulin single variable domains (ISVDs) that bind to human ISG15, thereby modulating various immune-related activities of the ISG15 protein. The invention further encompasses vectors and nucleic acids encoding these ISVD-based modulators, as well as pharmaceutical compositions containing such ISVD modulators. The ISG15-specific modulator polypeptides, particularly the ISVDs and compositions described herein, may be used for the prevention and / or treatment of immune-related disorders, including bacterial and viral infections, as well as autoimmune diseases.

The invention provides a detection kit for detecting interferon-related activating genes in neutrophil in a tumor microenvironment. The detection kit comprises an RNA extraction reagent, a reverse transcription reaction reagent, a quantitative PCR reagent, a probe, a positive reference substance and a negative reference substance. And the quantitative PCR reagent comprises upstream and downstream primers of nine interferon related genes, namely, ISG15 (Interferon Sorting Gene 15), RSAD2 (Registered Sequence Administration 2), IFIT1 (Interferon Institute of Transcription 1), IFI44L (Interferon Institute 44L), MX1, OAS1, STAT1, IRF7 and CXCL10. The detection kit can be used for detecting the expression quantity of nine genes including ISG15, RSAD2, IFIT1, IFI44L, MX1, OAS1, STAT1, IRF7 and CXCL10, accurate curative effect grouping is realized through dynamic monitoring of ISG15 + neutrophile granulocyte subpopulation, and meanwhile, improvement of curative effect prediction capability can be realized through combination with mrTRG.

This invention provides a targeted silver carp isg15 This invention relates to the sgRNA of a gene and its application in enhancing the resistance of fish to herpesviruses. It utilizes CRISPR / Cas9 technology to target and knock out the sgRNA of a silver carp. isg15-a Genes and isg15-b Genes were used to obtain F0 generation chimeras. The F0 generation underwent gynogenesis and selection to obtain... isg15 homozygous mutant silver carp isg15 ‑ / ‑ / ‑ Silver carp. After infection with crucian carp herpesvirus... isg15 ‑ / ‑ / ‑ The survival rate of silver carp was significantly increased; the expression of isg15 protein in tissues was significantly reduced; and viral genes were observed in the kidneys. 39ring The transcription level was significantly reduced. This demonstrates that the gene-edited fish prepared using the method of this invention have improved the crucian carp's resistance to herpesvirus, providing a foundation for disease-resistant breeding of silver crucian carp and also providing important reference value for disease-resistant breeding of other farmed fish.

The invention discloses application of long-chain non-coding RNA (LncRNA) XR002626937.1 in regulation and control of replication of canine coronavirus (CCoV), and belongs to the technical field of biological medicine. The nucleotide sequence of the LncRNA XR002626937.1 is as shown in SEQ ID No.1, is mainly positioned in a cell nucleus, is remarkably up-regulated in time and dose dependence after MDCK cells are infected by CCoV, and is positively correlated with virus load. Functional experiments prove that overexpression of the LncRNA can significantly promote CCoV replication, and knock-down of the expression of the LncRNA can effectively inhibit virus proliferation; the action mechanism comprises the steps of inhibiting activation of a p53 signal channel and downstream target genes p21 and Bax, repressing apoptosis of infected cells, antagonizing expression of natural immune factors such as RIG-I, MAVS, ISG15 and the like, promoting virus immune escape, and being capable of serving as competitive endogenous RNA to adsorb miR-10926-z to regulate and control the downstream signal channel. The key function of the LncRNA XR002626937.1 in CCoV infection is defined for the first time, a new target spot and a theoretical basis are provided for developing the anti-CCoV medicine targeting the LncRNA, and the application prospect is wide.

The invention discloses a CDKN2A and ISG15 interaction key site MET53 and an application of the CDKN2A and ISG15 interaction key site MET53. In particular to application of a CDKN2A protein MET53 site in preparation of products for diagnosing or inhibiting tumor immune escape, tumor epithelial-mesenchymal transition, tumor cell matrix metalloproteinase expression quantity and tumor cell PD-L1 level and a method for preparing cancer cells with inhibited invasion and metastasis capacity, and provides a new way for precise diagnosis and treatment of tumors. The important clinical application value is realized.

The invention relates to the field of tumor diagnosis and treatment, and provides application of CDKN2A and ISG15 proteins in diagnosis or treatment of brain metastasis of lung cancer. The invention particularly relates to application in preparation of products for diagnosing or inhibiting lung cancer brain metastasis, tumor immune escape, tumor epithelial-mesenchymal transition, tumor cell invasion and migration ability, tumor cell matrix metalloproteinase expression quantity and tumor cell PD-L1 level. The invention provides a more effective way for diagnosis or treatment of brain metastasis of lung cancer, and has important clinical application value.

Use of dihydrotanshinone I or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating and / or preventing a TREX1 gene defect related self-inflammatory disease. It is found that dihydrotanshinone I can effectively inhibit the activation of the cGAS-STING pathway and inhibit the nuclear entry of IRF3 and P65 in diABZI induced BMDMs cells. Further, it is found that dihydrotanshinone I can significantly alleviate the inflammatory response caused by the deletion of the Trex1 gene in mice ‑ / ‑ significantly inhibit the expression of type I interferon related genes (IFN-beta, ifit1, ifit2, Isg15 and Rsad2) in mouse bone marrow derived BMDMs, and dihydrotanshinone I can significantly alleviate the inflammatory response caused by the deletion of the Trex1 gene in mice ‑ / ‑ inflammatory response caused by the deletion of the TREX1 gene in mice.

Methods are provided for assessing risk of developing esophageal adenocarcinoma in a subject using one or more of the following marker genes / proteins: ISG15, LTF, CNDP2, DAD1, SET, UBE2N, S100P, and GPI. Methods are also provided for determining expression of one or more esophageal adenocarcinoma risk factors in a subject. Methods are also provided for treating esophageal adenocarcinoma in a subject, for preventing esophageal adenocarcinoma in a subject, for inhibiting or decreasing proliferation of esophageal adenocarcinoma cells, for inhibiting or decreasing migration of esophageal adenocarcinoma cells, or for increasing susceptibility to cytotoxicity or inducing cell death of esophageal adenocarcinoma cells.

This invention discloses the brown-spotted grouper. EfBAG4 The application of genes in combating neuronecrosis virus infection involves the field of genetic engineering technology. EfBAG4 The nucleotide sequence of the gene is shown in SEQ ID NO.1. Experiments have shown that overexpression... EfBAG4 The gene can significantly reduce RGNNV virus titers, decrease hepatocyte shedding and damage caused by viral infection, and effectively inhibit viral replication in host cells. It can also promote immune genes in fish. IRF3 , IRF7 , ISG15 and IFN‑α This invention enables precise antiviral immune activation through the expression of [specific expression]. It provides a novel drug intervention strategy for the prevention and treatment of RGNNV infection, and has significant application value in the control of RGNNV-related diseases in aquaculture.